SCHEMBL7079626

SCHEMBL7079626

CC(C)CCOc1ccc(C=O)cc1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.59
ALDH1A1 P00352 4/20 0.57
MAPT P10636 3/20 0.57
HPGD P15428 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
LMNA P02545 2/20 0.57
MAPK1 P28482 1/20 0.57
EPHX2 P34913 1/20 0.54
ALDH1A3 P47895 1/20 0.53
CYP2A6 P11509 1/20 0.48
GAA P10253 1/20 0.47
HTT P42858 1/20 0.47
S1PR1 P21453 1/20 0.44
S1PR5 Q9H228 1/20 0.44
TP53 P04637 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3068736 0.95 TDP1 (0.54) TDP1ALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL19018472 0.91 ALDH1A1 (0.60) TDP1ALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL8371512 0.89 ALDH1A1 (0.57) TDP1ALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL31498248 0.88 ALDH1A1 (0.57) TDP1ALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL11806698 0.87 ALDH1A1 (0.53) TDP1ALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL28512770 0.87 ALDH1A1 (0.53) TDP1ALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL7283005 0.86 RARB (0.56) TDP1ALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL21104599 0.86 ALDH1A1 (0.54) TDP1ALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL21104611 0.86 ALDH1A1 (0.54) TDP1ALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL9489504 0.86 ALDH1A1 (0.54) TDP1ALDH1A1MAPTHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023141432-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2023-07-27 WO disclosed
WO-2022214995-A1 PROBE DIRECTED TO ENZYME ALDH1A3 AND USE THEREOF IN THE DIAGNOSIS OF GLIOBLASTOMA UNIVERSITA' DEGLI STUDI DEL PIEMONTE ORIENTALE "A. AVOGADRO" (IT) 2022-10-13 WO disclosed
US-10655029-B2 Inkjet ink and coloring composition RICOH COMPANY, LTD. (JP) 2020-05-19 US disclosed
US-20180094155-A1 INKJET INK AND COLORING COMPOSITION RICOH COMPANY, LTD. (JP) 2018-04-05 US disclosed
US-20180094155-A1 INKJET INK AND COLORING COMPOSITION RICOH COMPANY, LTD. (JP) 2018-04-05 US disclosed
CN-105503652-B Cyano-containing resveratrol analogses and its production and use 延边大学 2017-12-05 CN disclosed
US-9592221-B2 Antibacterial agents: aryl myxopyronin derivatives RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2017-03-14 US disclosed
US-9592221-B2 Antibacterial agents: aryl myxopyronin derivatives RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2017-03-14 US disclosed
US-20160263083-A1 ANTIBACTERIAL AGENTS: ARYL MYXOPYRONIN DERIVATIVES RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2016-09-15 US disclosed
US-20160263083-A1 ANTIBACTERIAL AGENTS: ARYL MYXOPYRONIN DERIVATIVES RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2016-09-15 US disclosed
EP-1324971-A2 CINNAMIC ACID ESTER HAARMANN & REIMER GMBH (DE) 2003-07-09 EP disclosed
US-6531625-B2 Condensation of benzaldehyde with ester HAARMANN & REIMBER GMBH (DE) 2003-03-11 US disclosed
US-20020133038-A1 Cinnamic esters SYMRISE GMBH & CO. KG (DE) 2002-09-19 US disclosed
WO-2002020456-A2 PRODUCTION OF CINNAMIC ACID ESTERS HAARMANN & REIMER GMBH (DE) 2002-03-14 WO disclosed
EP-0454501-B1 Benzylidenethiazolidine derivatives, their preparation and their use for the inhibition of lipid peroxides SANKYO CO (JP) 2001-09-05 EP disclosed
EP-0839812-A1 Preparation of benzylthiazolidine derivatives Sankyo Company Limited (JP) 1998-05-06 EP disclosed
US-5387596-A Treating arteriosclerosis SANKYO COMPANY, LIMITED (JP) 1995-02-07 US disclosed
EP-0454501-A2 Benzylidenethiazolidine derivatives, their preparation and their use for the inhibition of lipid peroxides Sankyo Company Limited (JP) 1991-10-30 EP disclosed
US-4987132-A PLATELET ACTIVATING FACTOR ANTAGONISTS YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1991-01-22 US disclosed
EP-0279681-A2 Saturated heterocyclic carboxamide derivatives YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1988-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160263083-A1 ANTIBACTERIAL AGENTS: ARYL MYXOPYRONIN DERIVATIVES POLRMT, POLR1C, FBL TDP1 1637/4885ALDH1A1 1785/4885MAPT 4817/4885
US-20020133038-A1 Cinnamic esters ACACB, CES2, FASN TDP1 4707/4885ALDH1A1 158/4885MAPT 2774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.